Approach to Cefepime-Induced Neurotoxicity in the Setting of Chronic Kidney Disease: A Case Report and Review of Literature

Ariel Ruiz de Villa¹, Kipson Charles¹, Raghav Bassi¹, Sanjae Spencer¹, Yvette Bazikian¹

1. Internal Medicine, University of Central Florida College of Medicine, Graduate Medical Education/Hospital Corporation of America (HCA) Healthcare North Florida Regional Medical Center, Gainesville, USA

Corresponding author: Ariel Ruiz de Villa, ruizdevilla001@gmail.com

Abstract

Cefepime-induced neurotoxicity is well-known, but an under-recognized event that can present with a myriad of neurological findings ranging from myoclonus to seizures to comatose state. It is more prevalent in patients with impaired renal clearance as it is mainly cleared by the kidneys. We present a case of a 52-year-old female who was managed in the intensive care unit with severe encephalopathy following empiric antibiotic therapy with cefepime. Although we encountered some unforeseen difficulties executing our initial plan of renal replacement therapy, our patient was successfully treated with fluids and intravenous diuresis with furosemide and was ultimately discharged home with full recovery.

Categories: Internal Medicine
Keywords: hemodialysis, chronic kidney disease, cefepime, comatose, neurotoxicity

Introduction

Cefepime is a β-lactam antibiotic classified as a fourth-generation cephalosporin. It is highly effective against both Gram-positive and Gram-negative bacteria, is widely administered parenterally, and is often one of the first choices by clinicians due to its wide spectrum of coverage. A well-known but rarely recognized and underdiagnosed adverse effect of cefepime is neurotoxicity, particularly seen in patients with renal impairment. These patients are at increased risk because hepatic metabolism of cefepime is minimal with 85% of the drug excreted in the urine unchanged [1]. Herein, we present a case of a patient with acute kidney injury (AKI) with a baseline chronic kidney disease stage 3 (CKD) who was empirically treated with cefepime for community-acquired pneumonia and consequently developed significant neurologic toxicity, requiring management in the critical care setting. A literature review was conducted as we discuss our approach to care and recommendations for the management of patients with similar presentations.

Case Presentation

The critical care service was consulted to evaluate a 52-year-old Caucasian female who had been admitted to the hospital two days prior with a chief complaint of acute hemoptysis and dyspnea. She was later diagnosed with community-acquired pneumonia and subsequently treated with IV cefepime. The patient’s condition deteriorated and she was subsequently found to be unresponsive, exhibiting rhythmic myoclonic jerks more prominent in her upper and lower extremities. She was unable to follow commands or communicate, with a Glasgow Coma Scale (GCS) of 5 (1 eye, 1 verbal, 3 motor). A tracheostomy collar was in place with 15 L of oxygen delivered per minute. Breath sounds were coarse bilaterally with minimal elevation of the chest during inspiration. According to the bedside nurse report, the patient had been alert and oriented, able to endorse shortness of breath a few hours earlier. The patient’s current medications were reviewed for any offending agents that could be contributing to the patient’s mental status change (Table 1). Laboratory results from hours earlier were reviewed as well (Table 2). Urinalysis revealed glucosuria and proteinuria, which was otherwise unremarkable.
| Medication Name       | Dose/Frequency                  |
|----------------------|---------------------------------|
| Levothyroxine        | 88 mcg daily                    |
| Budesonide           | 0.25 mg twice daily inhaled     |
| Metoprolol succinate | 25 mg daily                     |
| Amlodipine           | 10 mg daily                     |
| Atorvastatin         | 20 mg daily                     |
| Gabapentin           | 300 mg three times daily        |
| Levosalbutamol       | 1.25 mg four timed daily inhaled|
| Regular insulin      | As per sliding scale            |
| Mycophenolate mofetil| 1000 mg twice daily             |
| Doxycycline          | 100 mg twice daily              |
| Cefepime             | 2g twice daily                  |

**TABLE 1: Patient’s current medications at the time of initial assessment**
### TABLE 2: Laboratory results available at the time of initial assessment

| Tests                | Results | References | Units     |
|----------------------|---------|------------|-----------|
| White blood count    | 15.4    | 4.0-10.5   | $10^3$ uL |
| Hemoglobin           | 8.3     | 13.7-17.5  | g/dL      |
| Hematocrit           | 26      | 40.1-51    | %         |
| Platelets            | 132     | 150-400    | $10^3$ uL |
| MCV                  | 86.7    | 79.0-92.2  | fL        |
| Sodium               | 141     | 136-145    | mmol/L    |
| Potassium            | 5.1     | 3.5-5.1    | mmol/L    |
| Chloride             | 111     | 98-107     | mmol/L    |
| Carbon dioxide       | 25      | 21-32      | meq/L     |
| Glucose              | 200     | 74-106     | mg/dL     |
| BUN                  | 73      | 7-18       | mg/dL     |
| Creatinine           | 2.29    | 0.6-1.30   | mg/dL     |
| GFR                  | 24      | 0-120      | mL/min    |
| Albumin              | 2.3     | 3.4-5.0    | g/dL      |
| Calcium              | 8.8     | 8.5-10.1   | mg/dL     |
| Phosphorus           | 4.7     | 2.5-4.9    | mg/dL     |
| Total bilirubin      | 0.5     | 0.2-1.0    | mg/dL     |
| AST                  | 17      | 15-37      | units/L   |
| ALT                  | 18      | 13-56      | units/L   |
| Magnesium            | 2.7     | 1.8-2.4    | mg/dL     |
| Lactic acid          | 0.58    | 0.4-2.0    | mmol/L    |
| TSH                  | 1.190   | 0.358-3.740| uIU/mL    |

MCV: mean corpuscular volume; BUN: blood urea nitrogen; GFR: glomerular filtration rate; AST: aspartate aminotransferase; ALT: alanine transaminase; TSH: thyroid-stimulating hormone

Chest CT scan on admission revealed bilateral lower lobe infiltrates consistent with pneumonia (Figure 1). On admission, the patient was treated with intravenous (IV) cefepime and oral doxycycline for empiric respiratory tract infection. Bedside arterial blood gas was consistent with hypoxic respiratory failure (Table 3).
FIGURE 1: CT scan of patient’s chest. Red arrows pointing at areas of disease consistent with bilateral pneumonia

| Test            | Result | Reference | Units   |
|-----------------|--------|-----------|---------|
| pH              | 7.26   | 7.35-7.45 | No units|
| pCO₂            | 47     | 35-48     | mmHg    |
| pO₂             | 69.9   | 83-108    | mmHg    |
| pO₂/FiO₂ ratio  | 199.7  | Ratio     | Ratio   |
| HCO₃            | 20.8   | 21-28     | mmol/L  |
| O₂ saturation   | 90.7   | 94-98     | %       |

TABLE 3: Arterial blood gas results with tracheostomy collar at 15 L O₂/min

For the past few years, the patient had been receiving treatment with the immune suppressant mycophenolic acid, for granulomatosis with polyangiitis. Since then, she had had recurrent mixed infections and hospitalizations. The patient’s husband was able to recall that in the past the patient had had adverse reactions to some antibiotics; however, he was not able to recall a specific drug. He alluded to the possibility of a penicillin derivative. This was not part of the list of allergies and medication intolerances on the patient’s chart.

Of note, the patient had been closely followed by a nephrologist for rapid decline in renal function. It was documented that the patient had a kidney biopsy showing diffuse and nodular diabetic nephropathy with severe arterio-arteriolar sclerosis and severe tubular compromise. After initial assessment and review, the
Frequent monitoring of EEG, the patient’s renal function, and plasma cefepime levels are recommended in likely to be the cause of the patient’s symptoms, and lastly, abnormally high concentrations of cefepime. After several days of discontinuing cefepime, no other underlying cause of metabolic or toxic encephalopathy that is periodic discharge with a triphasic appearance, symptoms and abnormal EEG findings that resolve several days after cefepime initiation, electroencephalogram (EEG) findings consistent with a generalized tonic-clonic discharge that progressed to a comatose state and myoclonic jerks that increased in frequency until intervention.

The diagnostic criteria for cefepime-induced neurotoxicity are as follows: neurological symptoms occurring several days after cefepime initiation, electroencephalogram (EEG) findings consistent with a generalized periodic discharge with a triphasic appearance, symptoms and abnormal EEG findings that resolve several days of discontinuing cefepime, no other underlying cause of metabolic or toxic encephalopathy that is likely to be the cause of the patient’s symptoms, and lastly, abnormally high concentrations of cefepime. Frequent monitoring of EEG, the patient’s renal function, and plasma cefepime levels are recommended in

A retrospective cohort study published in the European Society of Clinical Microbiology and Infectious Diseases found cefepime-induced neurotoxicity to occur in 100% of patients who had cefepime trough concentrations above 38.1 mg/L with the highest proportion of cases occurring in patients who had an effective glomerular filtration rate less than 30 mL/min [9]. Without obtaining an actual cefepime trough level in our case. However, having the knowledge that our patient received 6 grams of cefepime over 36 hours with a baseline GFR of 24 mL/min, it was fair to assume that her symptoms were caused by cefepime.

Discussion

Cefepime is a parenteral fourth-generation cephalosporin that is often used clinically to treat community-acquired and hospital-acquired pneumonia due to its broad anti-microbial effect on both Gram-positive organisms including methicillin-sensitive Staphylococcus aureus and Gram-negative organisms such as Pseudomonas aeruginosa [2]. It exerts its effect by binding to penicillin-binding proteins and ultimately disrupting cell wall synthesis [3]. It also is a stallwart against many of the plasmid and chromosome-mediated beta-lactamases and has increased activity against Enterobacteriaceae that are generally resistant to third-generation cephalosporins [2, 4]. Various randomized control trials in patients with moderate to severe community-acquired pneumonia who had a poor response to monotherapies with penicillin or cephalosporins played good clinical response to cefepime. The preferred dosing is generally 1-2 g intravenously over thirty minutes twice a day with maximum plasma concentrations being two to three times higher with intravenous use than when used intramuscularly [2, 3]. With respect to the pharmacokinetics of the drug, cefepime is renally eliminated with a half-life of 2-2.5 h and volume distribution of 13-22 L in healthy adults [3, 4]. The most common adverse effects include headache, nausea, diarrhea, rash, fever, erythema, and colitis [2, 3].

In critically ill patients who have renal failure, plasma trough concentrations are highly variable increasing the risk of toxicity [5]. In rare circumstances, cefepime has been linked to neurological side effects due to its ability to readily cross the blood-brain barrier. Adverse reactions can be further potentiated in patients with renal insufficiency due to decreased drug clearance [5, 6]. This has been postulated to occur through a concentration-dependent effect on gamma-aminobutyric acid type A (GABA-A) receptor modulation [4-6]. One center reported these neurological adverse effects to occur in only 0.2% of patients receiving cefepime [6]. The most common observed clinical symptoms were diminished level of consciousness (80%), disorientation/agitation (47%), and myoclonus (40%), with a small subset of patients experiencing seizures and non-convulsive status epilepticus [6, 7]. The patient presented in this case had a mixed and progressive clinical presentation of neurotoxicity as she experienced diminished level of consciousness that progressed to a comatose state and myoclonic jerks that increased in frequency until intervention.

At this point, aggressive intravenous fluid resuscitation at 150 cc/h of normal saline was initiated with daily intravenous diuresis with furosemide. With the limitation of reduced glomerular filtration rate, we expected a prolonged course of treatment. Over the next three days, this patient’s toxic/metabolic encephalopathy resolved and she returned to baseline neurological function. Furthermore, her AKI progressively improved. This approach proved effective but initially challenging as the patient had already received a total of 6 g of cefepime with a chronically reduced glomerular filtration rate (GFR).

She was then transferred to the inpatient hospitalist service for continued management of pneumonia. Both the patient and spouse were provided with a detailed explanation of the events leading to her medical complication. Additional emphasis was placed on the importance of listing medication intolerance and she chronically compromised renal function in future medical encounters. Furthermore, the patient was advised not to receive treatment with cephalosporins, more specifically cefepime. She was then discharged home after an additional five days of hospitalization.

Discussion

Cefepime is a parenteral fourth-generation cephalosporin that is often used clinically to treat community-acquired and hospital-acquired pneumonia due to its broad anti-microbial effect on both Gram-positive organisms including methicillin-sensitive Staphylococcus aureus and Gram-negative organisms such as Pseudomonas aeruginosa [2]. It exerts its effect by binding to penicillin-binding proteins and ultimately disrupting cell wall synthesis [3]. It also is a stallwart against many of the plasmid and chromosome-mediated beta-lactamases and has increased activity against Enterobacteriaceae that are generally resistant to third-generation cephalosporins [2, 4]. Various randomized control trials in patients with moderate to severe community-acquired pneumonia who had a poor response to monotherapies with penicillin or cephalosporins played good clinical response to cefepime. The preferred dosing is generally 1-2 g intravenously over thirty minutes twice a day with maximum plasma concentrations being two to three times higher with intravenous use than when used intramuscularly [2, 3]. With respect to the pharmacokinetics of the drug, cefepime is renally eliminated with a half-life of 2-2.5 h and volume distribution of 13-22 L in healthy adults [3, 4]. The most common adverse effects include headache, nausea, diarrhea, rash, fever, erythema, and colitis [2, 3].

In critically ill patients who have renal failure, plasma trough concentrations are highly variable increasing the risk of toxicity [5]. In rare circumstances, cefepime has been linked to neurological side effects due to its ability to readily cross the blood-brain barrier. Adverse reactions can be further potentiated in patients with renal insufficiency due to decreased drug clearance [5, 6]. This has been postulated to occur through a concentration-dependent effect on gamma-aminobutyric acid type A (GABA-A) receptor modulation [4-6]. One center reported these neurological adverse effects to occur in only 0.2% of patients receiving cefepime [6]. The most common observed clinical symptoms were diminished level of consciousness (80%), disorientation/agitation (47%), and myoclonus (40%), with a small subset of patients experiencing seizures and non-convulsive status epilepticus [6, 7]. The patient presented in this case had a mixed and progressive clinical presentation of neurotoxicity as she experienced diminished level of consciousness that progressed to a comatose state and myoclonic jerks that increased in frequency until intervention.

A retrospective cohort study published in the European Society of Clinical Microbiology and Infectious Diseases found cefepime-induced neurotoxicity to occur in 100% of patients who had cefepime trough concentrations above 38.1 mg/L with the highest proportion of cases occurring in patients who had an effective glomerular filtration rate less than 30 mL/min [9]. Without obtaining an actual cefepime trough level in our case. However, having the knowledge that our patient received 6 grams of cefepime over 36 h with a baseline GFR of 24 mL/min, it was fair to assume that her symptoms were caused by cefepime.

The diagnostic criteria for cefepime-induced neurotoxicity are as follows: neurological symptoms occurring several days after cefepime initiation, electroencephalogram (EEG) findings consistent with a generalized periodic discharge with a triphasic appearance, symptoms and abnormal EEG findings that resolve several days of discontinuing cefepime, no other underlying cause of metabolic or toxic encephalopathy that is likely to be the cause of the patient’s symptoms, and lastly, abnormally high concentrations of cefepime. Frequent monitoring of EEG, the patient’s renal function, and plasma cefepime levels are recommended in
patients at high risk for cefepime-induced neurotoxicity [7]. The only definitive treatment is the discontinuation of cefepime, which results in a 90% recovery rate in one to three days as seen in the case above. In emergency situations, hemodialysis can also be initiated to rapidly remove cefepime from the cerebrospinal fluid (CSF) and plasma, as a single 3-h session can remove up to 70% of a given dose [7]. Interestingly, in patients who had received anti-convulsive therapy, there was no improvement in mental status, however, there was evidence of a temporary slowing in the generalized periodic discharge on the EEG [7]. This further suggests that there is no beneficial role in adding anticonvulsive therapy [7].

The approach to this case was rather unique due to the occurrence of unforeseen events. The initial plan after establishing the diagnosis of cefepime-induced neurotoxicity was to initiate hemodialysis. However, after the placement of the hemodialysis (HD) catheter, the patient had continuous large volume blood loss from the catheter site requiring blood transfusion. It was at that point that the patient’s spouse requested no additional invasive procedures. Our treatment focus then switched to fluid administration with daily diuresis with furosemide. Over the course of 72 h, the patient progressively improved with stepwise resolution of her symptoms including resolution of mentation, respiratory function, and neural control of micturition.

Conclusions

Cefepime-induced neurotoxicity is an under-recognized event that can present with a myriad of neurological findings ranging from myoclonus to seizures to comatose state. It is crucial for clinicians to be able to identify patients on cefepime therapy who subsequently develop new-onset neurological symptoms especially if they have underlying chronic kidney disease as early recognition can prevent unnecessary testing and therapy, and management can be as simple as prompt discontinuation of cefepime, which has a favorable outcome in this process.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Ariel Ruiz de Villa, Kipson Charles, Raghav Bassi, Sanjae Spencer, Yvette Bazikian declare(s) this research was supported (in whole or in part) by from HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Lindsay H, Gruner S, Brackett J: Cefepime-induced neurotoxicity despite dose adjustment for renal disease: a brief report and review of the literature. J Pediatric Infect Dis Soc. 2017, 6:199-201. 10.1093/jpids/piw022
2. Chapman TM, Perry CM: Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003, 2:75-107. 10.1007/BF03256641
3. Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Mark A: Cefepime: a new fourth-generation cephalosporin. Am J Hosp Pharm. 1944, 51:463-77. 10.1093/ajhp/51.4.463
4. Okamoto MP, Nakahiro RK, Chin A, Bedikian A: Cefepime clinical pharmacokinetics. Clin Pharmacokinet. 1993, 25:88-102. 10.2165/00003088-199325020-00002
5. Boschung-Pasquier L, Atkinson A, Kastner LK, et al.: Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study. Clin Microbiol Infect. 2020, 26:335-9. 10.1016/j.cmi.2019.06.028
6. Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS: Characterizing cefepime neurotoxicity: a systematic review. Open Forum Infect Dis. 2017, 4: 10.1093/ofid/ofx170
7. Lee SJ: Cefepime-induced neurotoxicity. J Neurocrit Care. 2019, 12:74-84. 10.18700/jnc.190109